A double-blind placebo-controlled trial was conducted to assess the efficacy and safety of albendazole (400 mg twice daily for 3 weeks) for the treatment of Encephalitozoon intestinalis infection in patients with AIDS. Clearance of microsporidia from the intestinal tract was obtained in 4 of 4 patients in the albendazole group versus 0 of 4 in the control group (P Å .01, one-sided Fisher's exact test) and was associated with significant clinical benefit. All 4 controls subsequently cleared microsporidia following open-labeled albendazole treatment. To investigate the effect of albendazole in preventing relapse, these 8 patients were then randomly assigned to receive either albendazole (400 mg twice daily) or no treatment for the next 12 months. Albendazole significantly delayed the occurrence of relapse (P Å .04, one-sided log-rank test). In human immunodeficiency virus -infected patients with E. intestinalis infection, albendazole has parasitologic and clinical efficacy and reduces the risk of relapse.
Encephalitozoon intestinalis (formerly Septata intestinalis)
Uncontrolled studies have suggested that patients with E. intestinalis infections can experience symptomatic improveis a microsporidial species that has recently been recognized as an opportunistic pathogen in patients with AIDS [1, 2] . E.
ments with albendazole associated with clearance of the parasite from stools and follow-up intestinal biopsies [3 -5, 7 , 11 -intestinalis is a spore-forming protozoan parasite that predominantly infects the epithelial cells of the intestine and the biliary 14] . Symptomatic illness may, however, recur following completion of therapy [4, 5, 7, 12] . tract. As a result of infection of tissue macrophages, this parasite may also disseminate to other tissues, such as the urinary
The present report describes the results of a randomized study of albendazole for the treatment and prophylaxis of E. tract [3] . The main clinical manifestations of E. intestinalis infections are chronic diarrhea and cachexia that can be associintestinalis infections. Given the results of the first interim analysis, the independent study committee recommended that ated with cholangitis, sinusitis, bronchitis, conjunctivitis, and interstitial nephritis [3 -5] . Diagnosis of intestinal microsporienrollment of additional patients be discontinued. diosis can now be reliably made by detection of spores in stool samples using appropriate staining techniques [6, 7] . E.
Materials and Methods intestinalis infection is suspected when large spores are also found in the urine sediment, a unique feature of the genus Participants. To be enrolled in the study, human immunodeficiency virus antibody-positive patients had to be §18 years old, Encephalitozoon. Definitive species identification requires have microsporidial spores detected on two consecutive stool and electron microscopy or, more recently, polymerase chain reacurine examinations, have diarrhea (defined as three or more loose tion (PCR) analysis of intestinal biopsies, stools, or urine samor liquid stools per day for at least 3 days), and/or use antidiarrheal ples [1, 8 -10] .
medications.
Patients with any of the following findings were excluded: pregnancy or breast-feeding, absolute neutrophil count of õ750 1 10 6 / L, platelet count of õ50 1 10 6 /L, hemoglobin level of õ8.0 g/ Design. The first part of the study was a double-blind placebo- during follow-up. As this prophylaxis study was not blinded, all assessments were performed by physicians blinded to the treatPatients who cleared microsporidia from stools and follow-up duodenal biopsies were eligible for the second part of the study, ment. Safety end points. All adverse events were recorded, regardless which was intended to study the efficacy and safety of maintenance therapy with albendazole as prophylaxis for E. intestinalis infecof their relationship to study drugs. Toxicity was graded according to the World Health Organization scoring system. Safety was astion. Patients were randomized to receive either open-labeled albendazole (400 mg twice daily) or no maintenance therapy for sessed by incidence, type, and severity of adverse events.
Statistical analyses.
Comparison of efficacy between treata 12-month period or until parasitologic relapse or death.
Use of nonspecific antidiarrheal medications during the study ment groups was based on the percentages of patients who cleared their infection compared by a one-sided Fisher's exact test. This was permitted and recorded in the patient's stool diary. Patients were allowed to self-adjust their antidiarrheal treatment.
analysis was based on a modified intention-to-treat approach that included all eligible subjects. The planned sample size was 10 Diagnosis of E. intestinalis infection. Microsporidial spores were detected in stool and urine samples by using two different patients per group. Nonparametric paired Kruskal-Wallis tests for continuous variables and Fisher's exact tests for binary variables staining methods [6, 7] . A semiquantitative assessment of the number of spores per stool smear was performed as previously dewere used for comparing secondary end points. P õ .05 defined statistical significance. An interim analysis was planned after 10 scribed [15] . All eligible patients underwent upper gastroduodenal endoscopy with duodenal biopsy to confirm the infection and to randomized patients completed the double-blind study. For statistical analysis of prophylaxis measures in patients with identify the species involved using electron microscopy as previously described [8, 15, 16] . Species identification was also conparasitic eradication, the Kaplan-Meier method estimated the timeto-relapse from the monthly parasitic stool examinations. The 2 firmed by PCR with primer sets specific for E. intestinalis, as previously reported [9, 10] .
groups were compared by a one-sided log-rank test. Statistical analysis used SAS software (SAS Institute, Carey, NC).
Management and follow-up of E. intestinalis infection.
Baseline investigations included complete history and physical examination, complete blood cell count, CD4 T lymphocyte count, urinalysis, and serum biochemistry analyses (electrolytes and liver
Results

function tests). All participants underwent routine stool studies
Patients. From September 1994 to November 1996, 10 pabefore enrollment, including bacterial stool cultures, examination tients were enrolled in the study. Electron microscopy analysis for ova and parasites (including cryptosporidia), and toxin assays of duodenal biopsies and PCR results from stools and intestinal for Clostridium difficile. Patients were requested to keep a stool diary during the study period, as previously reported [15] . biopsies showed that 2 patients were not infected with E. intesPatient assessments were done 2 weeks before initiation of the tinalis but with Enterocytozoon bieneusi and Encephalitozoon allocated drug regimen, the day the study regimen was prescribed, hellem (data not shown). These 2 patients were excluded from and at 2 and 3 weeks after the initiation of the study regimen. At the analysis. a second gastroduodenal endoscopy with duodenal biopsy was In 1 case, only duodenal biopsy submitted for parasitologic performed to confirm parasitic eradication. Biopsies were handled as for baseline assessment. Once parasitic eradication was conexamination yielded microsporidia. Electron microscopic and firmed, the patient was eligible for the prophylaxis study.
histopathologic analyses failed to detect microsporidia but did as from stool, urine, and bile samples from the same patient Efficacy end points for treatment. The primary end point was (data not shown).
parasitic eradication from the intestinal tract, defined as two conMicrosporidial spores could be found in urine (7/8 patients) secutive stool samples negative for microsporidial spores and lack and also sputum, bronchoalveolar lavage fluid, nasal passages, of microsporidia in all follow-up duodenal biopsies. Secondary end points included semiquantitative assessment of the number of conjunctiva, and bile duct (1 patient each). PCR assays con- used antimotility drugs at baseline, but two did at the end of treatment. Similarly, all patients in the albendazole group had formed stools at the end of the treatment compared with none firmed electron microscopic species identification in 6 of the 7 other patients, and no amplification was obtained from the in the placebo group (100% vs. 0%, P Å .01, one-sided Fisher's exact test). Fever resolved in 1 (1/1) patient in the albendazole last patient [9, 10] . No coinfection with another intestinal pathogen was found in 7 patients before or during therapy.
group but persisted in 3 of 3 patients in the placebo group. Also, decreases in alkaline phosphatase and creatinine levels Only 1 patient had concomitant Cytomegalovirus duodenitis and C. difficile in stools.
were noted in the albendazole group (2/3 and 2/2, respectively) and associated with the disappearance of leukocyturia in 3 of All patients were homosexual men, all but 1 had already experienced AIDS-defining opportunistic diseases, and all had 3 patients. Open-labeled albendazole was then offered to the 4 patients õ55 CD4 cells/mm 3 . All patients had a history of chronic intermittent diarrhea (mean duration, 1 month; range, 10 -90 in the placebo group who did not clear microsporidia from stools. All completed a 21-day course of albendazole and days). At the time of randomization, all patients had diarrhea and abdominal discomfort. Fever (ú38ЊC) was documented in cleared E. intestinalis from follow-up stools and intestinal biopsies. The overall cure rate of the albendazole regimen in our 4 patients, cholangitis in 2, crampy abdominal pain in 1, nausea and vomiting in 2, and bronchitis and sinusitis in 2. Significant study was therefore 100% (8/8; 95% confidence interval, 0.64 -1). Urine analysis still yielded microsporidial spores in 3 of leukocyturia (20 -200/high-power field) was found in 4 patients associated with increase in creatinine levels in 2. Six patients these patients at the end of the treatment. Prophylaxis. After albendazole therapy, all 8 patients had had increased levels of alkaline phosphatase, and 4 had elevated levels of liver aminotransferases.
cleared microsporidial infection from their intestinal tract and were randomly assigned to receive either maintenance therapy Treatment of E. intestinalis microsporidiosis. There were no imbalances between study groups in baseline characteristics (table with albendazole (400 mg twice daily: 3 patients) or no treatment (5 patients). Two patients in the albendazole group and 1). Mean duration of treatment in the placebo group was 13.5 days (range, 4-21) versus 21 days in the albendazole group. Lack of 3 in the no-treatment group still had microsporidia in urine samples at that time. efficacy with persistent diarrhea was the reason for premature discontinuation in the placebo group. Parasitologic assessments The 2 groups remained well-balanced with respect to age, sex, AIDS-defining diseases, CD4 cell count, and duration of were, however, available for these patients. Microsporidial spores were always detected in follow-up stool and urine specimens from previous albendazole therapy (each patient had received 3 weeks of albendazole). Four patients received protease inhibipatients randomized to receive placebo with no change in the semiquantitative number of spores (data not shown). By contrast, tors (ritonavir or indinavir) during this trial, 2 in each group, starting a mean of 32 days (range, 0 -82) after randomization. clearance of microsporidial spores was observed in follow-up stool specimens from the 4 patients randomized to receive albendazole.
All 4 patients had similar CD4 cell counts. During the study period, none of the 3 patients receiving Urine specimens from 2 of these 4 patients still yielded microsporidia, although the spores appeared to be altered. These 4 patients maintenance therapy had a recurrence of E. intestinalis infection (mean follow-up, 7.7 months; range, 6 -9). Microsporidial underwent a second duodenal endoscopy with biopsies. These follow-up biopsies failed to yield microsporidia when examined spores were no longer detected in the urine samples from these patients. Three relapses were recorded among the 5 patients by histopathology and electron microscopy in 3 of 4 patients. In the 4th patient, electron microscopy only revealed what seemed receiving no prophylaxis, including both receiving protease inhibitors (mean follow-up, 2.7 months; range, 2 -3.3). The 2 to be remnant altered microsporidial spores. Eradication of intesti- [3, 5, 7, 11 -14] . Also, no patients receiving placebo. Parasitologic clearance was also associated with clinical benefit. The efficacy of albendazole is further other patients died without relapse after a 4-month follow-up.
supported by the fact that patients initially randomized to receive The comparison of the failure times between the 2 groups was placebo cleared their microsporidial infections following opensignificant (P Å .04, one-sided log-rank test).
labeled albendazole. Overall, as 8 of 8 patients cleared their Two of these relapses occurred in patients with persistent infection in our study, the cure rate with albendazole was 100% asymptomatic shedding of microsporidial spores in urine. Para-(95% confidence interval, 0.64-1). sitologic relapse was associated with diarrhea in only 1 patient A randomized double-blind controlled trial of albendazole (800 who had concomitant cryptosporidiosis. All 3 patients who mg twice daily for 2 weeks) in patients with AIDS and chronic relapsed received a further 3-week course of albendazole therdiarrhea has also been conducted in Zambia and has shown apy with parasitologic clearance.
remission of diarrhea in 26% of the patients receiving albendazole Death occurred in 4 patients during follow-up (in 3 receiving [21] . Albendazole was used empirically, however, without any no prophylaxis and in 1 receiving albendazole). By log-rank prior stool investigation. Since albendazole has broad activity analysis, albendazole had no significant effect on mortality against Strongyloides stercoralis, Giardia intestinalis, and miduring follow-up. Deaths were due to AIDS-related diseases in crosporidia, all of which can cause diarrhea in patients with 3 patients (non-Hodgkin's lymphoma, cerebral tumor, human AIDS, no definitive conclusion can be drawn from this trial immunodeficiency virus encephalopathy) and to staphylococcal about the efficacy of albendazole specifically on microsporidial bacteremia in 1.
infection [21] . Adverse drug reactions were mild during this study Adverse events (table 2) . Only one serious adverse event and never required the discontinuation of therapy. was reported during the double-blind period of the trial and
The only serious adverse event during our study was obinvolved a patient with concomitant Cytomegalovirus duodeserved in a patient randomized to receive placebo. Only mild nitis, randomized to the placebo group, who developed bacterial increases in aminotransferases could be associated with albenpneumonia and seizures after 17 days of treatment. This patient dazole therapy. The dosage of albendazole used in this study recovered after receiving broad-spectrum antibiotic therapy.
was similar to that used in hydatid cyst disease, in which up Ten nonserious adverse events were also reported during to 12 cycles of 28-day treatments have been given. Only rare the double-blind study, mostly headaches and gastrointestinal side effects were noted in that study, including nausea, alopecia, adverse events (table 2) . No long-term safety problems were rash, liver function abnormalities, and neutropenia [22] . recorded during maintenance therapy with albendazole.
Our second objective was to assess the efficacy of long-term maintenance therapy with albendazole to prevent relapses of this microsporidial infection. Indeed, although the efficacy of Discussion albendazole in the treatment of E. intestinalis infections had been suggested by previous studies, a number of relapses were Albendazole is a broad-spectrum antiparasitic agent with activity against protozoa, cestodes, and nematodes [17] . Albenalso noted within months of completing therapy, some of which occurred in patients still receiving low-dose albendazole dazole binds to the colchicine-sensitive site of tubulin, inhibiting its polymerization into microtubules, thus interfering with [4, 7, 11] . We therefore designed a randomized study to compare albennutrient uptake and cell division [18] . Albendazole has been previously used in patients with AIDS for the treatment of dazole (400 mg twice daily) with no treatment to investigate the ability of albendazole to prevent recurrent microsporidiosis infection with E. bieneusi, another microsporidial species [19, 20] . Although symptomatic improvement was noted in some and demonstrated that albendazole significantly delayed the occurrence of relapse. patients, there was no reduction in parasite burden, as spores
